344 related articles for article (PubMed ID: 30444176)
41. Vowel acoustics in Parkinson's disease and multiple sclerosis: comparison of clear, loud, and slow speaking conditions.
Tjaden K; Lam J; Wilding G
J Speech Lang Hear Res; 2013 Oct; 56(5):1485-502. PubMed ID: 23838989
[TBL] [Abstract][Full Text] [Related]
42. Effects of Intensive Voice Treatment (The Lee Silverman Voice Treatment [LSVT LOUD]) in Subjects With Multiple Sclerosis: A Pilot Study.
Baldanzi C; Crispiatico V; Foresti S; Groppo E; Rovaris M; Cattaneo D; Vitali C
J Voice; 2022 Jul; 36(4):585.e1-585.e13. PubMed ID: 32819780
[TBL] [Abstract][Full Text] [Related]
43. Neurobehavioral Effects of LSVT
Li Y; Tan M; Fan H; Wang EQ; Chen L; Li J; Chen X; Liu H
Front Neurosci; 2021; 15():624801. PubMed ID: 33716652
[TBL] [Abstract][Full Text] [Related]
44. Early detection of speech and voice disorders in Parkinson's disease patients treated with subthalamic nucleus deep brain stimulation: a 1-year follow-up study.
Tsuboi T; Watanabe H; Tanaka Y; Ohdake R; Hattori M; Kawabata K; Hara K; Ito M; Fujimoto Y; Nakatsubo D; Maesawa S; Kajita Y; Katsuno M; Sobue G
J Neural Transm (Vienna); 2017 Dec; 124(12):1547-1556. PubMed ID: 29098450
[TBL] [Abstract][Full Text] [Related]
45. Intensive voice treatment (the Lee Silverman Voice Treatment [LSVT
Ertan E; Gürvit HI; Hanağası HH; Bilgiç B; Tunçer MA; Yılmaz C
Logoped Phoniatr Vocol; 2022 Dec; 47(4):262-270. PubMed ID: 34287100
[No Abstract] [Full Text] [Related]
46. Lee Silverman Voice Treatment for people with Parkinson's: audit of outcomes in a routine clinic.
Wight S; Miller N
Int J Lang Commun Disord; 2015; 50(2):215-25. PubMed ID: 25469736
[TBL] [Abstract][Full Text] [Related]
47. Intensive Voice Treatment (Lee Silverman Voice Treatment [LSVT LOUD]) for Children With Down Syndrome: Phase I Outcomes.
Boliek CA; Halpern A; Hernandez K; Fox CM; Ramig L
J Speech Lang Hear Res; 2022 Apr; 65(4):1228-1262. PubMed ID: 35230877
[TBL] [Abstract][Full Text] [Related]
48. Speech-Breathing Treatment and LSVT for a Patient With Hypokinetic-Spastic Dysarthria After TBI.
Solomon NP; Makashay MJ; Kessler LS; Sullivan KW
J Med Speech Lang Pathol; 2004 Dec; 12(4):213-219. PubMed ID: 23946632
[TBL] [Abstract][Full Text] [Related]
49. Swallowing and voice effects of Lee Silverman Voice Treatment (LSVT): a pilot study.
El Sharkawi A; Ramig L; Logemann JA; Pauloski BR; Rademaker AW; Smith CH; Pawlas A; Baum S; Werner C
J Neurol Neurosurg Psychiatry; 2002 Jan; 72(1):31-6. PubMed ID: 11784821
[TBL] [Abstract][Full Text] [Related]
50. Acoustic evaluation of short-term effects of repetitive transcranial magnetic stimulation on motor aspects of speech in Parkinson's disease.
Eliasova I; Mekyska J; Kostalova M; Marecek R; Smekal Z; Rektorova I
J Neural Transm (Vienna); 2013 Apr; 120(4):597-605. PubMed ID: 23254927
[TBL] [Abstract][Full Text] [Related]
51. Comparison of two forms of intensive speech treatment for Parkinson disease.
Ramig LO; Countryman S; Thompson LL; Horii Y
J Speech Hear Res; 1995 Dec; 38(6):1232-51. PubMed ID: 8747817
[TBL] [Abstract][Full Text] [Related]
52. Markerless Analysis of Articulatory Movements in Patients With Parkinson's Disease.
Bandini A; Orlandi S; Giovannelli F; Felici A; Cincotta M; Clemente D; Vanni P; Zaccara G; Manfredi C
J Voice; 2016 Nov; 30(6):766.e1-766.e11. PubMed ID: 26620259
[TBL] [Abstract][Full Text] [Related]
53. Implementing two treatment approaches to childhood dysarthria.
Levy ES
Int J Speech Lang Pathol; 2014 Aug; 16(4):344-54. PubMed ID: 24673184
[TBL] [Abstract][Full Text] [Related]
54. Impact of clear, loud, and slow speech on scaled intelligibility and speech severity in Parkinson's disease and multiple sclerosis.
Tjaden K; Sussman JE; Wilding GE
J Speech Lang Hear Res; 2014 Jun; 57(3):779-92. PubMed ID: 24687042
[TBL] [Abstract][Full Text] [Related]
55. Feasibility and Acceptability of Lee Silverman Voice Treatment in Progressive Ataxias.
Lowit A; Egan A; Hadjivassiliou M
Cerebellum; 2020 Oct; 19(5):701-714. PubMed ID: 32588316
[TBL] [Abstract][Full Text] [Related]
56. Effects of SPEAK OUT! & LOUD Crowd on Functional Speech Measures in Parkinson's Disease.
Sullivan L; Martin E; Allison KM
Am J Speech Lang Pathol; 2024 Jul; 33(4):1930-1951. PubMed ID: 38838243
[TBL] [Abstract][Full Text] [Related]
57. Individual and environmental contributions to treatment outcomes following a neuroplasticity-principled speech treatment (LSVT LOUD) in children with dysarthria secondary to cerebral palsy: a case study review.
Boliek CA; Fox CM
Int J Speech Lang Pathol; 2014 Aug; 16(4):372-85. PubMed ID: 25011399
[TBL] [Abstract][Full Text] [Related]
58. Acoustic and Perceptual Consequences of Speech Cues for Mandarin Speakers With Parkinson's Disease.
Hsu SC; McAuliffe MJ; Lin P; Wu RM; Levy ES
Am J Speech Lang Pathol; 2019 May; 28(2):521-535. PubMed ID: 31136238
[TBL] [Abstract][Full Text] [Related]
59. Speech and language therapy treatment on hypokinetic dysarthria in Parkinson disease: Systematic review and meta-analysis.
Muñoz-Vigueras N; Prados-Román E; Valenza MC; Granados-Santiago M; Cabrera-Martos I; Rodríguez-Torres J; Torres-Sánchez I
Clin Rehabil; 2021 May; 35(5):639-655. PubMed ID: 33233932
[TBL] [Abstract][Full Text] [Related]
60. [Intrinsic and co-intrinsic vowel characteristics in cerebellar and parkinsonian dysarthrias].
Baudelle E; Vaissière J; Renard JL; Roubeau B; Chevrie-Müller C
Folia Phoniatr Logop; 2003; 55(3):137-46. PubMed ID: 12771465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
